Abstract
The discovery of a novel series of 2-(4-pyridyl)thienopyridinone GSK-3β inhibitors is reported. X-ray crystallography reveals its binding mode and enables rationalization of the SAR. The initial optimization of the template for improved cellular activity and predicted CNS penetration is also presented.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Cell Line
-
Central Nervous System / drug effects
-
Central Nervous System / metabolism
-
Crystallography, X-Ray
-
Dose-Response Relationship, Drug
-
Drug Discovery
-
Glycogen Synthase Kinase 3 / antagonists & inhibitors*
-
Glycogen Synthase Kinase 3 beta
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Permeability / drug effects
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyridones / chemical synthesis
-
Pyridones / chemistry
-
Pyridones / pharmacology*
-
Stereoisomerism
-
Structure-Activity Relationship
-
Thiophenes / chemical synthesis
-
Thiophenes / chemistry
-
Thiophenes / pharmacology*
Substances
-
Protein Kinase Inhibitors
-
Pyridones
-
Thiophenes
-
GSK3B protein, human
-
Glycogen Synthase Kinase 3 beta
-
Glycogen Synthase Kinase 3